Zymeworks Statistics
Share Statistics
Zymeworks has 69.68M
shares outstanding. The number of shares has increased by -1.6%
in one year.
| Shares Outstanding | 69.68M |
| Shares Change (YoY) | -1.6% |
| Shares Change (QoQ) | 1.02% |
| Owned by Institutions (%) | 87.59% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3,038 |
| FTD / Avg. Volume | 0.46% |
Short Selling Information
The latest short interest is 6.79M, so 9.75% of the outstanding
shares have been sold short.
| Short Interest | 6.79M |
| Short % of Shares Out | 9.75% |
| Short % of Float | 12.65% |
| Short Ratio (days to cover) | 14.48 |
Valuation Ratios
The PE ratio is -9.05 and the forward
PE ratio is -10.54.
Zymeworks's PEG ratio is
1.56.
| PE Ratio | -9.05 |
| Forward PE | -10.54 |
| PS Ratio | 14.55 |
| Forward PS | 4.1 |
| PB Ratio | 0 |
| P/FCF Ratio | -9.82 |
| PEG Ratio | 1.56 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Zymeworks.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.4,
with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.4 |
| Quick Ratio | 3.4 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | -175.28 |
| Debt / FCF | -163.36 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $255,197.32 |
| Profits Per Employee | $-410,351.17 |
| Employee Count | 299 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 6.08M |
| Effective Tax Rate | -5.22% |
Stock Price Statistics
The stock price has increased by 43.55% in the
last 52 weeks. The beta is 1.24, so Zymeworks's
price volatility has been higher than the market average.
| Beta | 1.24 |
| 52-Week Price Change | 43.55% |
| 50-Day Moving Average | 11.74 |
| 200-Day Moving Average | 13.02 |
| Relative Strength Index (RSI) | 54.61 |
| Average Volume (20 Days) | 661,673 |
Income Statement
In the last 12 months, Zymeworks had revenue of 76.3M
and earned -122.69M
in profits. Earnings per share was -1.62.
| Revenue | 76.3M |
| Gross Profit | 65.11M |
| Operating Income | -119.82M |
| Net Income | -122.69M |
| EBITDA | -105.42M |
| EBIT | -119.82M |
| Earnings Per Share (EPS) | -1.62 |
Full Income StatementBalance Sheet
The company has 66.1B in cash and 18.48B in
debt, giving a net cash position of 47.63B.
| Cash & Cash Equivalents | 66.1B |
| Total Debt | 18.48B |
| Net Cash | 47.63B |
| Retained Earnings | -830.34B |
| Total Assets | 425.52M |
| Working Capital | 241.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -110.04M
and capital expenditures -3.07M, giving a free cash flow of -113.11M.
| Operating Cash Flow | -110.04M |
| Capital Expenditures | -3.07M |
| Free Cash Flow | -113.11M |
| FCF Per Share | -1.49 |
Full Cash Flow StatementMargins
Gross margin is 85.33%, with operating and profit margins of -157.03% and -160.8%.
| Gross Margin | 85.33% |
| Operating Margin | -157.03% |
| Pretax Margin | -152.82% |
| Profit Margin | -160.8% |
| EBITDA Margin | -138.16% |
| EBIT Margin | -157.03% |
| FCF Margin | -148.24% |
